Old Web
English
Sign In
Acemap
>
authorDetail
>
S. Hartz
S. Hartz
Eli Lilly and Company
Medicine
Physical therapy
Internal medicine
Psoriasis
Ixekizumab
5
Papers
120
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index (PASI) values ≤1, 2, 3 or 5 derived from a statistical conversion method.
2021
Journal of The European Academy of Dermatology and Venereology
Ulrich Mrowietz
R.B. Warren
Craig L. Leonardi
Daniel Saure
Helmut Petto
S. Hartz
Martin Dossenbach
Kristian Reich
Show All
Source
Cite
Save
Citations (3)
THU0290 Effects of biologic dmards on physical function in patients with active psoriatic arthritis: results of network meta-analyses
2018
Annals of the Rheumatic Diseases
A. Ruyssen-Witrand
Christophe Sapin
S. Hartz
S Liu-Léage
Show All
Source
Cite
Save
Citations (1)
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
2017
British Journal of Dermatology
Kristian Reich
Andreas Pinter
Jean-Philippe Lacour
C. Ferrándiz
G. Micali
Lars E. French
M. Lomaga
Y. Dutronc
Carsten Henneges
Stefan Wilhelm
S. Hartz
C. Paul
Show All
Source
Cite
Save
Citations (108)
Elicitation of health state utilities associated with varying severities of flares in Systemic Lupus Erythematosus.
2015
Health and Quality of Life Outcomes
C. Pollard
S. Hartz
S. Liu Leage
M.A. Paget
J. Cook
A. Enstone
Show All
Source
Cite
Save
Citations (7)
1